GH001 is our innovative drug product for 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) administration via a proprietary inhalation approach. 


A healthy volunteer study with GH001 has been completed, establishing the safety of the inhalation approach and the appropriate GH001 dose range for further clinical studies.


A Phase 1/2 study with GH001 in patients with Treatment-Resistant Depression is ongoing.


GH002, our innovative injectable formulation of 5-MeO-DMT, is expected to enter the clinic soon.